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ABSTRACT.
Purpose: To assess quality of life (QoL) status via the National Comprehensive
Cancer Network (NCCN) distress thermometer as a psychooncological screen-
ing tool in uveal melanoma patients.
Methods: One hundred and six consecutive patients suffering from uveal
melanoma completed the distress thermometer between 04/2018 and 12/2018.
Practical, emotional, family concerned, spiritual, physical and overall distress
levels, distribution of distress and subgroup analyses defining groups of potential
high distress levels in need of intervention were assessed. Descriptive statistics,
cross-tabulations, chi-square and Fisher’s exact test as well as correlation
coefficients (Spearman’s rho) and receiver operating characteristic (ROC) were
used for analysis.
Results: Patients with higher T-category had significantly more emotional
problems and spiritual concerns (p = 0.046 and p = 0.023, respectively). Female
patients accounted for higher rates of physical issues (p = 0.034). Lower best
corrected visual acuity (BCVA) was correlated with higher distress levels
(p = 0.037). Patients resulting in loss of BCVA of ≥3 lines reported higher
distress levels (p = 0.029). A distress threshold of 5 on the basis of ROC analysis
showed a corresponding sensitivity of 100% and specificity of 76%.
Conclusion: The NCCN distress thermometer could be integrated well into our
clinical routine and proved to be a rapid, yet sensible screening tool for emotional
and physical distress in patients with uveal melanoma. Special attention should
be paid to patients with higher T-category and patients resulting in lower levels
of BCVA. As in patients with different tumour entities, the established distress
threshold of ≥5 proposing intervention proved to be adequate for uveal melanoma
patients.
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Introduction
Uveal melanoma is the most frequent
primary intraocular tumour in adults
(Singh & Topham 2003) with a
reported incidence of 5–7 per million
(Hu et al. 2005) and must be consid-
ered as a severe ocular and, due to the
risk of the development of metastases,
possibly life-threatening condition
(Lane et al. 2018). To date, good local
tumour control can be achieved in the
vast majority of cases (Gragoudas
et al. 1992) using different techniques
from eye-conserving plaque
brachytherapy, proton beam therapy,
stereotactic radiosurgery to enucle-
ation. As the results of the Collabora-
tive Ocular Melanoma Study (COMS)
could prove no survival difference
between globe-preserving treatment
and enucleation in the long-term fol-
low-up (COMS Group 2001), the effect
of the treatment chosen on the quality
of life (QoL) of the patients should be
considered for treatment planning
(Foss et al. 2000). Recent findings
within the literature on the develop-
ment of QoL seem to show no overall
treatment-related differences in QoL,
(van Beek et al. 2018; Miniati et al.
2018) but enucleated patients have
been reported to suffer more from
vision related problems (van Beek et al.
2018; Frenkel et al. 2018).
As Ophthalmologists, our focus is,
of course, primarily set on the good
results of local disease control. Yet, due
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to the patients’ confrontation with an
invasive and potentially metastatic
malignancy, their psychological dis-
tress during and after local therapy
should not be underestimated: the
presence of a serious disease by itself
can cause depression (Raison & Miller
2003) and high proportions of uveal
melanoma patients report reduced QoL
and substantial emotional problems
compared with other cancer diagnoses
and normative data (Brandberg et al.
1995, 2000; Hjermstad et al. 1998).
Different physiological and psycholog-
ical effects on the patients after enucle-
ation and globe-preserving therapy
have been reported in the literature
reflecting on their QoL (COMS Quality
of Life Study Group 1999; Chabert
et al. 2004).
In contrast to ongoing systemic
treatment regimen of different cancer
entities, uveal melanoma is commonly
treated in a single-session or hypofrac-
tionated procedure and severe ocular
adverse effects such as loss of vision,
optic neuropathy, secondary glaucoma
and cataract develop at a later time
throughout follow-up. Consequently,
patients stand alone soon after therapy
and monitoring of the tumour and all
related issues often lie within the
responsibility of the treating Ophthal-
mologist. We would therefore like to
implement a simple, quick and effective
screening tool regarding patients’ QoL
into our tumour outpatient clinic.
The NCCN distress thermometer is
a screening tool for assessment of
psychosocial stress, so-called distress,
with high acceptance, concision and
good practicability (Mehnert et al.
2006). In brief, it comprises a distress
scale from 0 to 10 as well as a problem
list including practical, family, emo-
tional, spiritual/religious and physical
problems or concerns. Cut-off values
≥5 imply that relevant psychological
pressure is present and assistance
should be offered. A problem list is
attached to the distress thermometer
designating in which field of life help
should be sought (e.g. reference to a
social worker, minister, Psychologist or
Oncologist) (Mehnert et al. 2006).
In our previous QoL-studies on
patients with uveal melanoma, we
focused on the devolution of QoL after
radiosurgery (Klingenstein et al. 2013)
and compared QoL after globe-pre-
serving therapy with that of patients
having undergone enucleation
employing the Short-form (SF)-12
Health Survey (Klingenstein et al.
2016). We could not find data about
the NCCN distress thermometer as a
screening tool for psychological and
emotional distress for uveal melanoma
patients in common medical databases,
so we conducted the present study to
evaluate which patients, at what point
in time throughout the course of their
disease and in which areas of life need
our medical and psychological support
most. Feasibility and patient accep-
tance of the distress thermometer in
our tumour outpatient department
were also recorded.
Material and methods
One hundred and six patients were
included consecutively from our
tumour consultation outpatient depart-
ment and gave informed consent to
complete the NCCN distress ther-
mometer (https://www.nccn.org/patie
nts/resources/life_with_cancer/pdf/ncc
n_distress_thermometer.pdf; German
version) during their routine follow-
up visit. All patients included had
sufficient knowledge of the German
language in order to complete the
questionnaire on their own. At each
visit, a complete ophthalmological
examination including standardized
A- and B-scan echography as well as
widefield fundus photography was per-
formed. Relevant patient data that
could have an influence on psychoon-
cological distress collected for statisti-
cal evaluation included patients’ sex,
age at primary diagnosis, age at com-
pletion of the questionnaire, tumour T-
category, tumour anatomic stage,
tumour location, local therapy mode,
time after therapy, best corrected visual
acuity (BCVA) of both eyes and in the
tumour eye prior to and after therapy,
number of chronic co-morbidities, ocu-
lar adverse effects and metastatic sta-
tus. Patient data were assessed between
04/2018 and 12/2018.
This study has approval of the
institutional review board of the
Department of Ophthalmology of Lud-
wig-Maximilians-University Munich/
Germany. Tumour staging was per-
formed using the AJCC Cancer Staging
Manual (7th ed. New York, NY:
Springer; 2009).
Data were collected in Microsoft
Excel (Microsoft Corporation, Red-
mond, WA, USA) for Mac 2011. All
statistical analyses were performed
using and SPSS 25.0 (IBM Corpora-
tion; Armonk, NY, USA) employing
descriptive statistics, cross-tabulations
including chi-square and Fisher’s exact
test, calculation of correlation coeffi-
cients (Spearman’s rho) as well as ROC
curve and Youden index. p < 0.05 was
considered statistically significant. All
confidence intervals reported are at
95% level.
Results
Demographic data
For demographic patient data (gender,
age, T-category, anatomic stage,
tumour location, therapy, BCVA of
the tumour eye, number of relevant co-
morbidities and metastatic status), see
Table 1.
Median time at completion of the
survey after primary diagnosis was 2.9
(range 0–29.5; mean 4.4  4.6 SD)
years. Median age at primary diagnosis
was 58.7 (range 24.1–84.9; mean
57.0  14.0 SD) years, and median
age at completion of the distress ther-
mometer was 64.2 (range 26.1–87.9;
mean 61.5  13.5 SD) years.
Thirty-five patients had no ocular
complications. In 71 of 106 patients
(67.0%), one or more ocular complica-
tion requiring therapy was noted
throughout follow-up (radiation
retinopathy n = 40/106 (37.7%), per-
sistent subretinal fluid n = 9 (8.5%),
phthisis n = 8 (7.5%), optic neuropa-
thy n = 6 (5.7%), secondary glaucoma
n = 5 (4.7%), vitreous haemorrhage
n = 3 (2.8%) and epiretinal gliosis
n = 1 (0.9%); cataract not included).
Three patients suffered from local
tumour recurrence (two patients after
brachytherapy and one patient after
CyberKnife radiosurgery).
Statistical evaluation
Median distress levels were 3.4 (range
0–10; mean 3.0  2.5 SD; box-plot see
Figure 1). Out of 106 patients, 25
(23.6%) reported practical problems,
11 (10.4%) family problems, 7 (6.6%)
religious or spiritual concerns, 64
(60.4%) emotional and 73 (68.9%)
physical problems (Figure 2, for list
of distress levels and problems reported
please see Table 2). Figure 3 shows the
distribution of emotional problems in
detail. Regarding patients’ physical
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problems, we considered the items
pain, fatigue, sleep and appearance as
most relevant after treatment of uveal
melanoma as patients do not undergo
chemotherapy and we think that there-
fore, further physical items listed are
not influenced directly by the treatment
of our patients. For detailed distribu-
tion of these physical problems, see
Figure 4a (for gender distribution see
Figure 4b).
Higher T-category was correlated
with a higher level of emotional prob-
lems (p = 0.046) and spiritual concerns
(p = 0.023; Fisher’s exact test, respec-
tively). Emotional problems and spiri-
tual concerns were correlated
(p = 0.040; Fisher’s exact test and
Spearman’s rho). Spiritual concerns
were also significantly higher in
patients with higher anatomic tumour
stage (p = 0.001; Fisher’s exact test).
Subgroup analysis showed that
female patients reported more physical
issues (p = 0.034; Fisher’s exact test).
BCVA of the untreated eye did not
correlate significantly with distress
levels (with BCVA of the non-me-
lanoma eye being median 0.0 (range
0.1 to 1.3, mean 0.07, SD 0.2) log
(MAR)). Yet, correlation coefficients
proved a significant correlation
between BCVA of the tumour eye after
therapy and patients’ distress levels
(p = 0.037; Spearman’s rho). We
hypothesized that at a BCVA < 0.5
log(MAR) of the tumour eye, stereop-
sis and binocularity can be maintained
and near-distance vision is above read-
ing ability which is important for
patients’ independence in everyday life.
We therefore performed a more
detailed subgroup analysis and could
find no statistical difference of distress
levels in patients with BCVA of <0.5
log(MAR) and ≥0.5 log(MAR) in the
tumour eye, but patients that suffered a
loss of BCVA ≥3 lines in the tumour
eye after therapy reported significantly
higher distress levels (p = 0.029; Fish-
er’s exact test).
All other items tested did not result
in statistically significant correlations
to the distress levels. Particularly sub-
group analysis of the time of comple-
tion of questionnaire after primary
diagnosis (0 to ≤6 months, n = 11/106
(10.4%); 6 to ≤36 months, n = 40/106
(37.7%) and >36 months, n = 55/106
(51.9%)) could prove no significant
differences of distress levels. This sub-
division was performed in order to
assess possible differences around pri-
mary diagnosis as well as regarding
short-term and long-term complica-
tions.
We calculated the area under the
curve (AUC) via receiver operating
Fig. 1. Box-plot showing the overall distribution of distress on the NCCN distress thermometer
(n = 106 patients).
Table 1. Demographic patient characteristics (n = 106)
Sex Male: Female [47:59]
Median age at primary diagnosis 59 [range 24–85] y
Median age at interview 64 [range 26–88] y
T stage T1 = 43
T2 = 38
T3 = 21
T4 = 4
Anatomic stage 1 = 41
2A = 36
2B = 19
3A = 7
4 = 3
Tumour location Peripapillary = 20
Posterior pole = 16
Mid-periphery = 43
Periphery = 25
Ciliary body = 2
Eye Right = 45
Left = 61
Therapy CyberKnife radiosurgery = 82
Brachytherapy = 10
Enucleation = 10
Proton beam therapy = 3
Gammaknife radiosurgery = 1
BCVA [log(MAR)] Prior to therapy:
Median 0.5, mean 0.5, SD  0.3
After therapy:
Median 1.1, mean 1.4, SD  1.1
N° of relevant co-morbidities None = 46
1 = 37
2 = 17
3 = 6
Development of metastases 5
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characteristic (ROC) analysis and came
to the conclusion, that the best
combination of sensitivity (100%) and
specificity (76%) regarding psychoon-
cological distress was at a cut-off of a
level of ≥5 on the distress thermometer
(highest Youden index 0.76).
Thirty three patients (31.1%)
reported a distress level of ≥5 and thus
were offered specific support in relation
to their problems by employing this
cut-off level. Upon direct approach, 11
of these patients (10.4%) had already
been provided with psychooncological
support. Acute intervention to lessen
emotional or practical problems was
initiated in 10 patients by the treating
physicians of the study team (9.4%).
These patients were advised psychoon-
cological help; additionally, rehabilita-
tion was planned for 2 (1.9%) patients
in order to improve practical issues.
Acute ophthalmological interven-
tion was performed as follows to
relieve physical problems resulting in
high distress levels: Enucleation due to
secondary glaucoma and associated
pain in 2 (1.9%), intravitreal therapy
due to radiation neuropathy and con-
sequent macular oedema in 2 (1.9%) as
well as exoresection and pars-plana-
vitrectomy in one patient due to vitre-
ous haemorrhage in order to improve
BCVA in the tumour eye, respectively.
The remaining seven patients either
declined active support and/or stated
that their distress level did not result
from their uveal melanoma (e.g. recent
death of a close family member).
Overall, the distress thermometer
proved rapid and feasible during rou-
tine examination of the tumour
patients in our outpatient department
and was well tolerated and accepted by
our patients.
Discussion
Health-related QoL research is indis-
pensable as it provides insights into
domains that are not directly observ-
able (Desouky et al. 2012) for the
treating clinician.
In this patient collective, over 60%
of patients reported emotional prob-
lems with higher T-category leading to
significantly more emotional problems
and spiritual concerns. Screening of
these patients and early intervention is
crucial as different meta-analyses have
shown that QoL can be improved
through psychosocial interventions
and relaxation trainings (Meyer &
Mark 1995; L€ubbert et al. 2001).
Over 68% of patients reported phys-
ical issues upon request with female
patients accounting for significantly
higher rates of physical issues
(p = 0.034). This is in accordance with
a recent cross-sectional study that
reported women tending to express
more dissatisfaction with care (Afshar
et al. 2018).
Table 2. Patients’ answers on the NCCN
Distress Thermometer and complete problem
list (n = 106)
Distress levels 0 = 11 (10.4%)
1 = 15 (14.2%)
2 = 21 (19.8%)
3 = 12 (11.3%)
4 = 14 (13.2%)
5 = 14 (13.2%)
6 = 3 (2.8%)
7 = 8 (7.5%)
8 = 4 (3.8%)
9 = 1 (0.9%)
10 = 3 (2.8%)
Practical problems overall 25 (23.6%)
Child care 1 (0.9%)
Housing 4 (3.8%)
Insurance/financial 8 (7.5%)
Transportation 12 (11.3%)
Work/school 15 (14.2%)
Family problems overall 11 (10.4%)
Dealing with children 8 (7.5%)
Dealing with partner 6 (5.7%)
Emotional problems overall 64 (60.4%)
Depression 11 (10.4%)
Fears 41 (38.7%)
Nervousness 31 (29.2%)
Sadness 21 (19.8%)
Worry 36 (34.0%)
Loss of interest in usual
activities
14 (13.2%)
Spiritual/religious concerns
overall
7 (6.0%)
Loss of faith 4 (3.8%)
Relating to God 3 (2.8%)
Physical problems overall 73 (68.9%)
Appearance 4 (3.8%)
Bathing/dressing 1 (0.9%)
Breathing 7 (6.0%)
Changes in urination 6 (5.7%)
Constipation 3 (2.8%)
Diarrhea 4 (3.8%)
Eating 3 (2.8%)
Fatigue 31 (29.2%)
Feeling swollen 3 (2.8%)
Fevers 0 (0.0%)
Getting around 24 (22.6%)
Indigestion 8 (7.5%)
Memory/concentration 21 (19.8%)
Mouth sores 10 (9.4%)
Nausea 4 (3.8%)
Nose dry/congested 14 (13.2%)
Pain 25 (23.6%)
Sexual 7 (6.0%)
Skin dry/itchy 19 (18.0%)
Sleep 33 (31.1%)
Tingling in hands/feet 13 (12.3%)
Fig. 2. Overall frequency distribution of practical and family problems, religious or spiritual
concerns, emotional and physical problems via vertical bar graph (n = 106 patients).
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Moschos et al. (2018) recently proved
that level of depression is correlated
with decrease in BCVA in uveal mela-
noma patients. In our previous QoL-
study employing the SF-12 health sur-
vey on uveal melanoma patients after
CyberKnife radiosurgery, patients
with better BCVA reported higher
QoL at 2 years of follow-up (Klingen-
stein et al. 2013). This finding could now
be confirmed by the NCCN distress
thermometer: Lower BCVA in the
tumour eye was correlated with higher
distress levels (p = 0.037). When look-
ing more into detail, patients suffering
from loss of BCVA of ≥3 lines of the
treated eye had significantly higher dis-
tress levels (p = 0.029). Thus, preserva-
tion of BCVA should be a key point of
local tumour therapy. Continuous long-
term psychosocial treatment is needed
from the time of diagnosis in a subgroup
of patients suffering from eye-related
disabilities (Frenkel et al. 2018).
We found that the distress ther-
mometer form can be included easily
into daily practice. As department of
Ophthalmology, we received positive
feedback from the patients in distribut-
ing the form, saying that they often felt
left alone with emotional and physical
problems. Patients reported that as
non-metastatic uveal melanoma does
not require chemotherapy, therapy is
often single-session or hypofractionated
and visual impairment following
therapy is often not directly visible and
delayed, acceptance within society as a
highly malignant disease is poor. Other
than in oncological patients who have
to undergo months of difficult treat-
ment cycles, offering psychological
assistance to uveal melanoma patients
may not be a top priority for the
treating doctors. According to the liter-
ature, only few uveal melanoma
patients (13.3%) reported an offer of
psychological support and most dissat-
isfaction in this US American patient
collective was with lack of advice on
financial aspects of care and lack of
psychological counselling (Afshar et al.
2018).
Our patients tended to report their
fears (e.g. of blindness) or feelings that
the disease was not taken seriously
solely upon means of targeted ques-
tioning. The NCCN distress ther-
mometer functioned as an ice-breaker
in these cases and uncovered the need
of assistance not only for new patients,
but also for patients whom we have
been accompanying for long-term fol-
low-up. Critical points in time through-
out the course of cancer are reportedly
the primary diagnosis, treatment end-
point, recurrence or disease progres-
sion as well as the palliative stage (Mc
Cormick & Conley 1995). A survey
polling uveal melanoma patients one
and 3 months after diagnosis cited
most importantly the need of health
information and psychological needs
(Williamson et al. 2018). This suggests
that early on, the severity of such needs
and psychosocial factors that may be
associated can be identified for proac-
tive supportive intervention (Wil-
liamson et al. 2018). In our study, we
found no statistical impact of time after
diagnosis on distress levels using the
NCCN distress thermometer. Neither
freshly diagnosed patients nor patients
after more than 3 years of follow-up,
after which time all treatment-related
adverse effects would be expected. In
consequence, continuous long-term
psychosocial screening is needed, but
with the NCCN distress thermometer,
this can be integrated into clinical
practice easily.
Apart from the NCCN distress ther-
mometer, there are a multitude of
valuable questionnaires for assessment
of patients’ QoL (e.g. the SF-36 or -12
Health Survey or the European Organ-
isation into Research and Treatment of
Cancer (EORTC) QLQ-C30). The
authors have reported their study expe-
rience with the SF-12 Health Survey
previously (Klingenstein et al. 2013,
2016). For the EORTC, there is an
additional EORTC QLQ-OPT30 mod-
ule consisting of 30 items for uveal
melanoma patients (Brandberg et al.
2004). Yet, a combination of question-
naires and modules may exceed the
recommended maximum of 30 items
(Sprangers et al. 1998), needing more
time and concentration for fulfilment,
possibly influencing the patients’ com-
pliance.
The NCCN distress thermometer
that we employed now is an ultra-short
screening tool on just one single page
including the distress thermometer as a
visual analog scale, thus allowing very
rapid completion. No complex addi-
tional scoring software is needed for
interpretation, which in our experience
with the SF-12 Health Survey might
result in a delay of therapy initiation.
Another advantage of the NCCN dis-
tress thermometer is very clear interpre-
tation of the data acquired with a
distress level of 5 or above resulting in
proposition and initiation of proactive
support by the caregivers. The area of
life that needs active intervention can
also be distinguished at a glance (e.g.
practical problems are presented to a
social worker or the patients’ health
insurance, emotional and family prob-
lems require psychooncological
Fig. 3. Detailed distribution of emotional problems via vertical bar graph (n = 106 patients).
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counselling, religious or spiritual con-
cerns are taken to the minister and
physical impairment should be
improved by us as the patients’ treating
physicians). For the most part, for
example when employing the SF-12
Health Survey, after complex evaluation
of the different items, only a differenti-
ation between physical and emotional
health problems can be performed leav-
ing the initiation of help much less
specific for the treating physician.
A sensitivity of 97% and specificity
of 41% were reported for the German
version of the distress thermometer
(Mehnert et al. 2006). We found for
our patient collective, that as advised in
the guidelines of the distress thermome-
ter (Mehnert et al. 2006), and derived
from our ROC analysis, active inter-
vention was sensible and needed in
distress values ≥5 (100% sensitivity and
76% specificity). This proves that our
uveal melanoma patient collective can
be considered comparable to other
oncological patient groups within the
literature. A brief and direct screening
approach of uveal melanoma patients
employing the NCCN questionnaire is
helpful. It showed well, in which area
of life the patients required assistance.
In a recent large multicenter evalu-
ation of an initially cancer-free patient
collective diagnosed with cancer later
during the study period, death rates in
the most distressed group were consis-
tently raised for cancer of all sites in
comparison with the least distressed
group (Batty et al. 2017). Conversely,
detection and early treatment of dis-
tress could also be secondarily preven-
tive for further psychiatric as well as
somatic diseases (Batty et al. 2017).
This pilot study for the employment
of the NCCN distress thermometer in
uveal melanoma patients has proven
promising results and warrants its
advantages as a screening tool. Further
studies should be initiated to validate
and support these findings.
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